CLSD Company Profile and Key Details

CLSD has shown weak momentum, losing -84.29% over the past week and -92.56% over the past quarter, though year-to-date performance is down -97.12%. Short-term trend indicators are bullishly aligned (SMA20 -86.23%, SMA50 -88.61%, SMA200 -95.46%). The stock’s 14-day RSI is 16.06 (weak momentum), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.6% below its high and over 10.78% above its low.

Clearside Biomedical, Inc. generated EPS of -$5.06 over the past year. Five-year average earnings growth is 10.4%. Wall Street analysts project EPS growth of 22.36% annually over the next five years. The latest quarter delivered EPS of -$1.14. The next quarter is forecast at -$0.60. Next year's EPS is expected at -$7.14. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $3.00. The high target offers 1119.51% upside. The low target suggests 631.71% downside. The mean target is $4.00. This offers 875.61% upside. Clearside Biomedical, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by 70.15%. The prior quarter beat by -50.0%. Over the last six quarters, Apple has recorded several small beats. These include -28.57% in August 12, 2024.

Clearside Biomedical, Inc. has 78.51 million shares outstanding. The public float is 4.54 million shares, elevated short interest at 0.15% of float. This equals 114.66 thousand shares. The short ratio is 2.31 days. Institutional investors hold 17.07% of the float. Insiders own 12.88%. White Daniel H. holds 483.34 thousand shares, LASEZKAY GEORGE M has 466.58 thousand shares and WHITMORE BRADFORD T has 444.44 thousand shares.

Our AI price prediction model suggests that Clearside Biomedical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by March 23, 2026, within a range of $0.00 to $0.90 3-Month Outlook: Projected fall of -73.17%, reaching $0.11 by June 05, 2026, with a range of $0.00 to $0.57. 1-Year Outlook: Projected loss of -95.12%, with price at $0.02 by March 09, 2027, within a range of $0.00 to $0.91.

Clearside Biomedical, Inc. (NASDAQ:CLSD) shares are down -97.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Clearside Biomedical, Inc. trading at a premium to the broader market with a P/E of -0.11. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $7.56, suggesting 1743.9% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-73.17% over three months), and a longer-term loss (-95.12% over one year), with expected trading ranges indicating moderate volatility.